Current Allergy and Asthma Reports

, Volume 13, Issue 5, pp 469–476

Rationale and Clinical Results of Inhibiting Interleukin-5 for the Treatment of Severe Asthma

Authors

  • Rachid Berair
    • Department of Respiratory Medicine, Thoracic Surgery, and Allergy, Institute for Lung and HealthGlenfield Hospital
    • Department of Infection, Immunity and InflammationUniversity of Leicester Medical School
    • Department of Respiratory Medicine, Thoracic Surgery, and Allergy, Institute for Lung and HealthGlenfield Hospital
ASTHMA (WJ CALHOUN AND SP PETERS, SECTION EDITORS)

DOI: 10.1007/s11882-013-0379-3

Cite this article as:
Berair, R. & Pavord, I.D. Curr Allergy Asthma Rep (2013) 13: 469. doi:10.1007/s11882-013-0379-3

Abstract

Severe asthma is responsible for considerable morbidity and a high proportion of the healthcare costs attributable to asthma. Management is not straightforward as the clinical, pathological and physiological features are heterogeneous and the relationships between these features are poorly understood. In recent years significant progress has been made in understanding this heterogeneity and eosinophilic asthma has emerged as a potentially clinically important phenotype because treatment with monoclonal antibodies against IL-5 is effective. This has required a change in our understanding of the role of eosinophilic airway inflammation in airways disease and the developments of reliable biomarkers of eosinophilic airway inflammation. We will review these developments and describe the clinical experience so far with treatment with monoclonal antibiotics against IL-5.

Keywords

AsthmaEosinophilsInterleukin-5IL-5InhibitingInhibitionMepolizumabSevere asthmaTreatment

List of Abbreviations

AHR

Airway hyperresponsiveness

BAL

Bronchoalveolar lavage

ECP

Eosinophil cationic protein

EDN

Eosinophil-derived neurotoxin

EPO

Eosinophil peroxidise

FeNO

Exhaled nitric oxide concentration

GM-CSF

Granulocyte-macrophage colony-stimulating factor

IgE

Immunoglobulin E

IL-5

Interleukin-5

MBP

Major basic protein

RCT

Randomised controlled trial

RNA

Ribonucleic acid

ROS

Reactive oxygen species

Th2

Type 2 T helper

Copyright information

© Springer Science+Business Media New York 2013